cft

PPK-188, also known as CFT, is a novel selective covalent inhibitor of tryparedoxin (tpx), efficiently killing live african trypansosomes

CFT7455 (Cemsidomide) is an anti-cancer agent showing high affinity to the cereblon E3 ligase with a Kd of 0.9 nM. CFT7455 is an orally active degrader of zinc finger transcription factors Ikaros (IKZF1), and Aiolos (IKZF3).

CFT-2718 is an advanced BRD4-targeting PROTAC (proteolysis-targeting chimera) known for its improved catalytic efficiency and superior in vivo characteristics.

CFT-1297 is a BET PROTAC degrader that targets BRD4 for degradation.

CFT-0743 could inhibits tumor growth (81% regression) potently with PDC50 value of 0.18 nM.

BETA-CFT sulfate is a derivative of BETA-CFT, an antagonist of dopamine transporter proteins (DATs).

(Rac)-CFT7455 is an Ikaros/Aiolos degradation agent that acts via the ubiquitin proteasome pathway and is able to act on NCIH929.1 cells (GI50: 0.05 nM). (Rac)-CFT7455 is a racemic isomer of CFT7455 and has anticancer activity.

CFT8634 is an orally active and selective degrader targeting BRD9, with effects on the proliferation of SMARCB1-deficient cancer cell lines. CFT8634 induces the formation of a ternary complex with BRD9 and E3 ligase, inducing BRD9 ubiquitination and subsequent degradation by the proteasome.

(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader with potential for researching BRD9-mediated disorders, such as abnormal cellular proliferation [1].

Tagarafdeg (CFT1946) is an orally available PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (type III) mutations, and the p61-BRAF V600E splice variant. It exhibits favourable selectivity within the proteome, including for wild-type BRAF and CRAF, and inhibits tumour cell proliferation.

CFTR corrector 4 is a potent and orally available transmembrane conductance regulator (CFTR) for cystic fibrosis and is a potent (R,R) type active enantiomer. CFTR corrector 4 increases CFTR levels on the cell surface and is a potential compound for the study of cystic fibrosis.

CFTR corrector 8 is a highly effective modulator of the cystic fibrosis transmembrane conductance regulator (CFTR). This compound is specifically designed for utilization in research related to cystic fibrosis, a genetic disorder primarily affecting the lungs and digestive system [1].

CFTR corrector 12 is a CFTR corrector that rescues all mutant proteins except M760R ABCA3, and can be used to study cystic fibrosis.

CFTRcorrector 16 (Compound 39) is a corrector of the cystic fibrosis transmembrane conductance regulator (CFTR), utilized in the research of cystic fibrosis disease.

CFTRcorrector 17 (example 17) is a regulator of the cystic fibrosis transmembrane conductance regulator (CFTR). It is utilized in the study of diseases mediated by CFTR.

CFTR activator 2 (WAY-326769) is an activator of mutant CFTR (cystic fibrosis transmembrane conductance regulator), which increases ion transport activity and can be used for research into cystic fibrosis (CF).

CFTRcorrector 18 (Compound I-99) acts as a modulator of the cystic fibrosis transmembrane conductance regulator (CFTR). It enhances the processing and trafficking of CFTR, thereby increasing the amount of CFTR present on the cell surface. CFTRcorrector 18 holds potential for research in cystic fibrosis (CF).

CFTRpotentiator 1 (I1421) is a potent CFTR potentiator with an EC50 value of 64 nM. It allosterically activates various mutations causing cystic fibrosis, such as ΔF508 and G551DCFTR.

BCFTP is a potent, orally active, and selective positive allosteric modulator of the human Mas-related G protein-coupled receptor X1 (MrgprX1). It selectively enhances MrgprX1 signaling in HEK293 cells. In a humanized MrgprX1 chronic constriction injury (CCI) mouse model, BCFTP alleviates specific neuropathic pain-related behaviors in an MrgprX1-dependent manner. Additionally, BCFTP synergistically enhances the analgesic effects with psychoactive substances in CCI MrgprX1 mice. This compound can be used for research in neuropathic pain.

CFTR(inh)-172 (CFTR Inhibitor-172) is a voltage-independent, selective CFTR inhibitor.

CFTR corrector 6 is a highly effective CFTR potentiator utilized in research on cystic fibrosis (CF) and related CFTR-associated disorders[1]. This potent compound exhibits potentiation activity on the Cystic Fibrosis Transmembrane conductance Regulator (CFTR), rendering it beneficial for investigations in CF and other associated conditions.

CFTR corrector 2 (FDL169) is a novel and potent CFTR (Cystic fibrosis transmembrane conductance regulator) corrector for treating cystic fibrosis (CF) patients who carry the F508del mutation.

CFTR Corrector 9, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, is employed in the research of cystic fibrosis (CF) and related CFTR-associated disorders [1].

CFTRcorrector 14 (Compound SVQ26) functions as a Class 3 corrector targeting the cystic fibrosis transmembrane conductance regulator (CFTR), enhancing CFTR activity (improving activity in the presence of Class 1 corrector VX-809 with an EC50 of 3.08 μM). It addresses the misfolding and functional impairments of CFTR proteins caused by mutations. CFTRcorrector 14 is used in cystic fibrosis research.